| Year |
Citation |
Score |
| 2023 |
Davis JD, Bravo Padros M, Conrado DJ, Ganguly S, Guan X, Hassan HE, Hazra A, Irvin SC, Jayachandran P, Kosloski MP, Lin KJ, Mukherjee K, Paccaly A, Papachristos A, Partridge MA, et al. Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development. Clinical Pharmacology and Therapeutics. PMID 38093583 DOI: 10.1002/cpt.3150 |
0.318 |
|
| 2017 |
Kosloski M, Zhao W, Asatryan A, Kort J, Geoffroy P, Liu W. No Clinically Relevant Drug-Drug Interactions Between Methadone or Buprenorphine/Naloxone and Anti-Viral Combination Glecaprevir and Pibrentasvir. Antimicrobial Agents and Chemotherapy. PMID 28807904 DOI: 10.1128/Aac.00958-17 |
0.331 |
|
| 2016 |
Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-Factor VIII antibodies in Hemophilia A mice. Biopharmaceutics & Drug Disposition. PMID 27418232 DOI: 10.1002/Bdd.2023 |
0.738 |
|
| 2015 |
Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice. Journal of Pharmaceutical Sciences. 104: 388-95. PMID 24700333 DOI: 10.1002/Jps.23963 |
0.739 |
|
| 2014 |
Kosloski MP, Shetty KA, Wakabayashi H, Fay PJ, Balu-Iyer SV. Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo. The Aaps Journal. 16: 1038-45. PMID 24934295 DOI: 10.1208/S12248-014-9627-2 |
0.674 |
|
| 2014 |
Kosloski MP, Pisal DS, Mager DE, Balu-Iyer SV. Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. Biopharmaceutics & Drug Disposition. 35: 154-63. PMID 24259187 DOI: 10.1002/Bdd.1880 |
0.769 |
|
| 2013 |
Kosloski MP, Pisal DS, Mager DE, Balu-Iyer SV. Allometry of factor VIII and informed scaling of next-generation therapeutic proteins. Journal of Pharmaceutical Sciences. 102: 2380-94. PMID 23620343 DOI: 10.1002/Jps.23566 |
0.733 |
|
| 2012 |
Pisal DS, Kosloski MP, Middaugh CR, Bankert RB, Balu-Iyer SV. Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice. Journal of Pharmaceutical Sciences. 101: 2055-65. PMID 22388918 DOI: 10.1002/Jps.23091 |
0.761 |
|
| 2012 |
Peng A, Kosloski MP, Nakamura G, Ding H, Balu-Iyer SV. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice. The Aaps Journal. 14: 35-42. PMID 22173945 DOI: 10.1208/S12248-011-9309-2 |
0.784 |
|
| 2011 |
Kosloski MP, Peng A, Varma PR, Fathallah AM, Miclea RD, Mager DE, Balu-iyer SV. Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates. Drug Delivery. 18: 246-54. PMID 21114461 DOI: 10.3109/10717544.2010.536269 |
0.754 |
|
| 2010 |
Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. Journal of Pharmaceutical Sciences. 99: 2557-75. PMID 20049941 DOI: 10.1002/Jps.22054 |
0.739 |
|
| 2010 |
Rao G, Iyer V, Kosloski MP, Pisal DS, Shin E, Middaugh CR, Balu-Iyer SV. Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics. Journal of Pharmaceutical Sciences. 99: 1697-706. PMID 19798762 DOI: 10.1002/Jps.21938 |
0.752 |
|
| 2009 |
Peng A, Gaitonde P, Kosloski MP, Miclea RD, Varma P, Balu-Iyer SV. Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. Journal of Pharmaceutical Sciences. 98: 4480-4. PMID 19499565 DOI: 10.1002/Jps.21765 |
0.71 |
|
| 2009 |
Kosloski MP, Miclea RD, Balu-Iyer SV. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. The Aaps Journal. 11: 424-31. PMID 19499345 DOI: 10.1208/S12248-009-9119-Y |
0.753 |
|
| Show low-probability matches. |